Acquired Autoimmune Hemolytic Anemia Market Report 2026

The acquired autoimmune hemolytic anemia market size has grown strongly in recent years. It will grow from $2.14 billion in 2025 to $2.29 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to improved autoimmune disease diagnosis, corticosteroid treatment reliance, hospital hematology specialization, increased malignancy-linked anemia cases, diagnostic test availability.

The acquired autoimmune hemolytic anemia market size is expected to see strong growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rare disease awareness growth, biologic therapy adoption, advanced diagnostic integration, hematology research funding, personalized treatment protocols. Major trends in the forecast period include increasing use of targeted immunosuppressive therapies, rising adoption of rituximab-based treatment, growth in hospital-based hematology care, improved diagnostic testing adoption, expansion of rare disease treatment programs.

The rising prevalence of autoimmune disorders is expected to drive the growth of the acquired autoimmune hemolytic anemia market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body’s own healthy cells and tissues, perceiving them as harmful invaders. The increasing prevalence of autoimmune disorders is mainly linked to heightened environmental triggers and lifestyle changes that can disrupt normal immune system regulation. This rise in autoimmune disorders leads to a greater occurrence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more prone to developing secondary AIHA due to immune system dysfunction. For example, in 2023, the Gastro-Intestinal Epidemiology Consortium (CanGIEC), a Canada-based national network of researchers and clinicians, reported the prevalence of inflammatory bowel disease at approximately 825 cases per 100,000 people. This prevalence is projected to increase by 2.44% annually, reaching 1,075 cases per 100,000 people by 2035. Therefore, the growing prevalence of autoimmune disorders is expected to propel the acquired autoimmune hemolytic anemia market.

Major companies operating in the acquired autoimmune hemolytic anemia market are concentrating on advancements in targeted therapies, such as neonatal Fc receptor (FcRn) blockers, to enhance treatment effectiveness, improve maternal-fetal outcomes, and offer more efficient interventions for high-risk pregnancies affected by severe hemolytic disease. An FcRn blocker is a therapeutic antibody developed to inhibit the neonatal Fc receptor, which is responsible for recycling immunoglobulin G (IgG) antibodies in the body, thereby lowering pathogenic antibody levels that cause red blood cell destruction and hemolytic complications in both maternal and fetal populations. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical and healthcare company, received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for nipocalimab for the treatment of individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab works by selectively blocking the neonatal Fc receptor (FcRn), decreasing maternal IgG antibody levels that cross the placenta and attack fetal red blood cells, thereby preventing severe hemolytic disease, reducing the need for intrauterine transfusions, and improving outcomes for at-risk pregnancies. Nipocalimab specifically targets FcRn-mediated IgG recycling without impacting other immune functions.

In September 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired the Asian market rights to obexelimab, a bifunctional monoclonal antibody, from Zenas BioPharma for $50 million. Through this acquisition, Bristol Myers Squibb intends to expand its immunology portfolio and enhance its presence in the Asian biopharmaceutical market focused on autoimmune diseases. Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company that specializes in developing immunology-focused therapies for autoimmune conditions, including acquired autoimmune hemolytic anemia.

Major companies operating in the acquired autoimmune hemolytic anemia market are F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Novartis AG, Incyte Corporation, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Johnson & Johnson, Merck KGaA, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A.

North America was the largest region in the acquired autoimmune hemolytic anemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acquired autoimmune hemolytic anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the acquired autoimmune hemolytic anemia market by increasing the cost of imported biologics, immunosuppressive agents, and diagnostic reagents. These impacts have been most pronounced in biologic-based treatment segments, particularly in north america and europe where sourcing is globally diversified. Asia-pacific healthcare systems have faced pricing pressures in diagnostic imports. However, tariffs have encouraged domestic production of corticosteroids and localized diagnostic manufacturing, supporting treatment accessibility.

The acquired autoimmune hemolytic anemia market research report is one of a series of new reports that provides acquired autoimmune hemolytic anemia market statistics, including acquired autoimmune hemolytic anemia industry global market size, regional shares, competitors with a acquired autoimmune hemolytic anemia market share, detailed acquired autoimmune hemolytic anemia market segments, market trends and opportunities, and any further data you may need to thrive in the acquired autoimmune hemolytic anemia industry. This acquired autoimmune hemolytic anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acquired autoimmune hemolytic anemia (AIHA) is an uncommon condition that leads to anemia when the immune system mistakenly attacks and destroys the body's own red blood cells. It is often triggered by infections, autoimmune diseases, cancers, or certain medications, and it may develop suddenly or gradually. This occurs because the body produces antibodies that target its own red blood cells, resulting in hemolysis, or the early destruction of these cells.

The primary diagnostic approaches for acquired autoimmune hemolytic anemia include complete blood count, peripheral blood smear, direct Coombs test, and indirect Coombs test. A complete blood count (CBC) is a test used to identify anemia by assessing reduced hemoglobin and hematocrit levels, along with an increased reticulocyte count, reflecting enhanced red blood cell destruction. Treatment options include corticosteroids, immunosuppressive agents, intravenous immunoglobulin, and rituximab. The disease can range in severity from mild to moderate to severe. The main end users are hospitals, specialty clinics, and research institutions.

The acquired autoimmune hemolytic anemia market consists of revenues earned by entities by providing services such as diagnosis services, treatment and medication services, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired autoimmune hemolytic anemia market also includes sales of prednisone, and methylprednisolone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.